HeartSciences Inc. Form 8-K Summary
Business Context and Reporting Period
HeartSciences Inc. (HSCS), an emerging growth company incorporated in Texas, filed this Current Report on April 30, 2026. The filing details the results of the Annual Meeting of Stockholders held on the same date for the fiscal year ended April 30, 2025. The company's common stock and warrants trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a corporate governance report regarding shareholder voting results and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
As of the record date (March 6, 2026), 3,477,698 shares of common stock and Series C Convertible Preferred Stock (on an as-converted basis) were outstanding. A quorum was established with 1,973,863 shares (57%) present in person or by proxy. The voting outcomes were as follows:
- Proposal 1 (Election of Directors): Andrew Simpson was elected to a three-year term. Votes: 577,840 For, 107,738 Withheld, 1,288,285 Broker Non-Votes.
- Proposal 2 (Amendment of 2023 Employee Stock Purchase Plan): Approved. Shareholders voted to increase the share reserve to 1,250,000 shares plus an annual adjustment mechanism. Votes: 359,995 For, 323,187 Against, 2,395 Abstained.
- Proposal 3 (Amendment of Certificate of Formation for Officer Exculpation): Not Approved. The proposal failed to secure the required affirmative vote of a majority of the aggregate of common stock and Series C Preferred Stock (on an as-converted basis) voting as a single class. Votes: 542,609 For, 133,919 Against, 9,050 Abstained.
- Proposal 4 (Auditor Ratification): Approved. Haskell & White LLP was ratified as the independent registered public accounting firm for the fiscal year ending April 30, 2026. Votes: 1,872,912 For, 91,205 Against, 9,745 Abstained.
- Proposal 5 (Adjournment): Approved. Shareholders authorized adjournments to solicit additional proxies if necessary. Votes: 1,784,662 For, 185,241 Against, 3,958 Abstained.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this report, other than the failure of Proposal 3 to pass, which indicates a lack of shareholder consensus on expanding officer exculpation protections under Texas law.
Key Facts for Investor Verification
- Verify the specific voting threshold requirements for Proposal 3 to understand why the officer exculpation amendment failed despite a majority of votes cast being "For."
- Confirm the impact of the approved increase in the 2023 Equity Incentive Plan share reserve on future dilution.
- Review the definitive proxy statement filed on March 17, 2026, for detailed rationale behind the proposals and the composition of the Series C Preferred Stock.
- Note the high number of broker non-votes (approx. 1.29 million) on the director election and officer exculpation proposals, indicating significant passive ownership.